Integra LifeSciences Holdings (IART) has drawn investor attention after recent share price weakness, with the stock down over the past week, month, and past 3 months despite a positive year to date return.
Short term momentum for Integra LifeSciences Holdings has faded, with the share price down 3.1% over one day and 14.2% over three months. This comes even though the year to date share price return is 29.3% and the 1 year total shareholder return is 11.7%.
Scan how Integra LifeSciences Holdings compares with other potential turnaround stories by reviewing our hand picked list of 16 high quality undiscovered gems in similar market situations.
Integra LifeSciences Holdings now trades at a sizeable discount to both analyst targets and an estimated fair value, even after a strong year to date rebound. Is that a pricing error, or justified caution on a loss making business?
Most Popular Narrative: 42% Undervalued
Against Integra LifeSciences Holdings' last close of $15.53, the most followed narrative anchors fair value at $27.00 and frames the current price as a steep discount built on execution risk and remediation progress.
Analysts broadly agree that Integra's Compliance Master Plan and supply chain upgrades will stabilize operations and restore revenue. However, this may actually drive a structural step change in cost efficiency and supply reliability, which could lead to gross margin and earnings expansion beyond conservative estimates as operational bottlenecks are addressed across legacy and newly acquired sites.
See why 2 investors see Integra LifeSciences Holdings as 42% undervalued.
Result: Fair Value of $27.00 (UNDERVALUED)
Still, Integra LifeSciences Holdings faces ongoing regulatory and product recall risks, and slower customer recovery after shipholds could quickly challenge the view that the stock is 42% undervalued.
Find out about the key risks to this Integra LifeSciences Holdings narrative.
Next Steps
Mixed messages in the Integra LifeSciences Holdings story can make it hard to know which side to trust, so review the full data set and pressure test the bullish and cautious arguments for yourself by starting with our breakdown of 3 key rewards and 1 important warning sign.
Looking for more Integra LifeSciences Holdings style ideas?
If Integra LifeSciences Holdings has you rethinking your watchlist, use this moment to refresh your playbook with new, data backed ideas before the market moves.
- Target potential upside with a tight focus on quality by scanning the 30 high quality undervalued stocks that pass strict fundamental checks.
- Strengthen income potential by reviewing the 7 dividend fortresses that combine higher yields with robust payout support.
- Dial down portfolio risk by filtering for the 30 resilient stocks with low risk scores that pair resilient balance sheets with steadier business models.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com